Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Making Cashews Safer for Those with Allergies

Published: Wednesday, August 13, 2014
Last Updated: Wednesday, August 13, 2014
Bookmark and Share
Scientists now develop a method to process cashews to make them safer to eat.

For the millions of adults and children in the U.S. who have to shun nuts to avoid an allergic reaction, help could be on the way. Scientists are now developing a method to process cashews - and potentially other nuts - that could make them safer to eat for people who are allergic to them.

The researchers are presenting their work at the 248th National Meeting & Exposition of the American Chemical Society (ACS), the world’s largest scientific society. The meeting, being held here through Thursday, features nearly 12,000 presentations on a wide range of science topics.

“The only widely accepted practice for preventing an allergic reaction to nuts is strict avoidance - stay away from the food,” notes Chris Mattison, Ph.D. “Clinical trials to test immunotherapy are underway, but we’re approaching it from an agricultural perspective rather than medical. Can we change the food, instead of treating the person, so we can eliminate or reduce severe reactions?”

For those with food allergies, responses to offending products can range from mild itching in the mouth or skin to life-threatening anaphylaxis, which makes it hard to breathe. Once every three minutes, someone in the U.S. ends up in the emergency room due to a food allergy reaction - that adds up to about 200,000 visits a year.

To try to reduce those numbers, Mattison’s team is looking at ways to modify proteins in tree nuts and peanuts (which are legumes) that trigger an immune response in people who are allergic. The response is launched by antibodies called immunoglobulin E (IgE), which recognize and latch onto the proteins. Mattison explains that changing the shape of the proteins makes it harder for IgE to find them.

But past research taking this approach has involved harsh chemicals. Mattison, a researcher with the Agricultural Research Service branch of the U.S. Department of Agriculture, wanted to see if his team could achieve the same results, but using compounds that are “generally regarded as safe,” or GRAS. These are substances that are accepted by the Food and Drug Administration for use in food and pharmaceuticals.

“We found that the GRAS compound sodium sulfite can effectively disrupt the structure of a couple of the cashew allergens,” Mattison says. “And we’ve done a couple of different tests to show we reduced IgE binding to the proteins when they’ve been treated with sodium sulfite.”

Next, they plan to conduct experiments on whole nuts and test the modified proteins on cells in the lab to see how they respond. They’re also looking at enzymes, which are molecules that can cut up proteins, as candidates to disrupt the allergens.

And, although this particular report focuses on cashew proteins, Mattison says the work could have broader implications. The kinds of allergenic proteins the GRAS compound and enzymes affect are not exclusive to one kind of nut.

“One of our goals is to apply our knowledge from the cashew experiments to other tree nuts and to peanuts,” he says.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!